ChromaDex Appoints Harvard Medical School Professor of Neurology, Dr. Rudolph Tanzi, to the Scientific Advisory Board

IRVINE, Calif., June 27, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that it has appointed Dr.  Rudolph Tanzi, Vice-Chair of Neurology and … [Read more...]

Catalyst Pharmaceuticals Joins Russell 3000 Index

CORAL GABLES, Fla., June 26, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today announced that the company has been added to the broad-market Russell 3000® Index at the conclusion of the … [Read more...]

Neothetics Announces Top-Line Results for Phase 2 Proof-of-Concept Study of LIPO-202 for the Reduction of Submental Subcutaneous Fat

SAN DIEGO, June 26, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced top-line safety and efficacy results from its Phase 2 proof-of-concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat. LIPO-202 did not demonstrate improvement … [Read more...]

Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Presented at the European Hematologic Association (EHA) Congress in Madrid, Spain

AMES, Iowa, June 23, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the presentation of data from the Phase 1b portion of a study of indoximod, an IDO pathway inhibitor, in combination with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia (AML).  Abstract E-912, Indoximod in Combination with Idarubicin and … [Read more...]

Noblegen Announces the Opening of Its Second Round of Financing: Peterborough-based biotechnology startup targeting up to $50 million in equity financing

PETERBOROUGH, Ontario, June 22, 2017 (GLOBE NEWSWIRE) -- Today Peterborough based Noblegen announces the opening of its series B round of financing after the closing of a successful series A round that saw the firm raise $9.5 million in private investment. A photo accompanying this announcement is available at … [Read more...]